Angina Pectoris Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Angina Pectoris is chest pain or
discomfort resulting from atherosclerotic heart disease. It is a symptom of
coronary artery disease (CAD) that occurs when the heart muscle doesn't get as
much blood as needed, usually because one or more arteries are narrowed or
blocked. People experiencing angina feel uncomfortable pressure, fullness,
squeezing, or pain in the center of the chest. It is rarely sharply localized
and is typically not spasmodic. The distribution of the discomfort may vary
widely in different patients, but it does not usually differ from episode to
episode for a single patient. It can be stable or unstable. Stable angina
describes predictable chest pain caused by exertion or mental or emotional
stress, occurring consistently for a month or more. Unstable angina is a chest
pain of coronary origin arising in response to progressively less exercise or
fewer other stimuli than ordinarily required to produce angina or angina that
is a change in pattern from stable angina.
- The prevalence of Angina Pectoris in the USA varies from 4.5
MN to 5.2 MN among more than 40 years population.
Thelansis’s “Angina Pectoris Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Angina
Pectoris treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Angina Pectoris across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Angina Pectoris Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment